Document And Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Type Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Marketable securities Marketable securities - current Receivables, Long-Term Contracts or Programs Receivable from collaboration partner Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total current assets Marketable Securities, Noncurrent Marketable securities - noncurrent Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Restricted Cash, Noncurrent Restricted cash - noncurrent Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Other Accounts Payable and Accrued Liabilities Accrued expenses and other payables Deferred Income, Current Deferred revenue Operating Lease, Liability, Current Operating lease liability Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Operating lease liability - noncurrent Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding Common Stock, Value, Issued Common stock, $0.00001 par value, 180,000,000 shares authorized; 64,227,057 and 62,577,897 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive (loss) income Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balance, Ending Balance, Beginning Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Balance, Ending (in shares) Balance, Beginning (in shares) Common stock, shares outstanding Condensed Consolidated Statements of Operations Revenue from Contract with Customer, Including Assessed Tax License and collaboration revenue Revenue Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Investment Income, Interest Interest income Other Nonoperating Income (Expense) Other income, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) before income tax benefit Income Tax Expense (Benefit) Income tax benefit Income tax benefit (expense) Net income (loss) Net income (loss) Earnings Per Share, Basic Net income (loss) per share, basic Basic net income (loss) per share of common stock Earnings Per Share, Diluted Net income (loss) per share, diluted Diluted net income (loss) per share of common stock Weighted Average Number of Shares Outstanding, Basic Weighted-average shares used to compute net income (loss) per share, basic Weighted-average shares of common stock, basic Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares used to compute net income (loss) per share, diluted Weighted-average shares of common stock, dilutive Condensed Consolidated Statements of Comprehensive Income (Loss) Other Comprehensive Income (Loss), Net of Tax, Period Change [Abstract] Other comprehensive (loss) income: OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized (loss) gain on marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Condensed Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-In Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive (Loss) Income Retained Earnings [Member] Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Issuance of common stock under equity incentive and employee stock purchase plans Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Issuance of common stock under equity incentive and employee stock purchase plans (in shares) Represents shares withheld for net settlement of tax withholding upon vesting of restricted stock units. Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units Shares withheld for net settlement of tax withholding upon vesting of restricted stock units Represents the number of shares withheld for net settlement of tax withholding upon vesting of restricted stock units. Shares Withheld for Net Settlement of Tax Withholding Upon Vesting of Restricted Stock Units, Shares Shares withheld for net settlement of tax withholding upon vesting of restricted stock units (in shares) Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Issuance of common stock upon exercise of Warrants Number of warrants exercised during the current period. Stock Issued During Period, Shares, Warrants Exercised Issuance of common stock upon exercise of Warrants (in shares) Number of shares issued upon exercise of warrants APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive (loss) income Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Amount of Non-cash lease expense. Non-cash Lease Expense Non-cash lease expense Depreciation, Depletion and Amortization Depreciation Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount on marketable securities Other Operating Activities, Cash Flow Statement Other Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Amount of increase (decrease) in receivables from collaboration partner. Increase (Decrease) In Receivables From Collaboration Partner Receivable from collaboration partner Increase (Decrease) in Contract with Customer, Asset Contract asset Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accrued expenses and other payables Increase (Decrease) in Contract with Customer, Liability Deferred revenue Increase (Decrease) in Income Taxes Payable Income taxes payable Increase (Decrease) in Operating Lease Liability Operating lease liability Net Cash Provided by (Used in) Operating Activities Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows from Investing Activities Payments to Acquire Debt Securities, Available-for-Sale Purchase of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Proceeds from maturities of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Proceeds from sale of marketable securities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan Represents shares withheld for net settlement of tax withholding upon vesting of restricted stock units. Shares Withheld for Net Settlement of Tax Withholding Upon Vesting of Restricted Stock Units Tax withholding payments related to net settlement of restricted stock units The amount of proceeds from exercise of warrants in exchange for issuance of pre-funded warrants. Proceeds from Exercise of Warrants in Exchange for Issuance of Pre-funded Warrants Proceeds from exercise of Warrants in exchange for issuance of Pre-Funded Warrants Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Total cash reported on consolidated statements of cash flows Noncash Investing and Financing Items [Abstract] Supplemental Disclosure of Non-Cash Financing and Investing Information: Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment in accounts payable and accrued liabilities Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Description of Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies No definition available. License and Collaboration Agreements Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] The license and collaboration agreement with Janssen Biotech, Inc. (Janssen) dated May 26, 2017. License and Collaboration Agreement. Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] License and Collaboration Agreements Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements NA Cash Equivalents and Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Cash Equivalents and Marketable Securities Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components Stockholders' Equity Equity [Text Block] Stockholders' Equity Income Taxes Income Tax Disclosure [Text Block] Income Taxes Net Income (Loss) per Share Earnings Per Share [Text Block] Net Income (Loss) per Share Segment Reporting Segment Reporting Disclosure [Text Block] Segment Reporting Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation and Consolidation Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash as Reported in Condensed Consolidated Statements of Cash Flows Compensation Related Costs, Policy [Policy Text Block] Stock-Based Compensation Expense New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted as of March 31, 2026 Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of cash as reported in the condensed consolidated statements of cash flows Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of fair value of financial assets Marketable Securities [Table Text Block] Schedule of cash equivalents and marketable securities Schedule of Other Current Assets [Table Text Block] Summary of prepaid expenses and other current assets Property, Plant and Equipment [Table Text Block] Summary of property and equipment net Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accrued expenses and other payables Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of the basic and diluted net income (loss) per share Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of segment revenue, segment profit (loss) and significant expenses Represents the number of therapeutic areas that programs fall into. Number Of Therapeutic Areas Number of therapeutic areas Line of Credit Facility [Table] Pledged Status [Axis] Pledged Status [Domain] Asset Pledged as Collateral [Member] Asset pledged as collateral Restricted Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash [Member] Cash Line of Credit Facility [Line Items] Summary of Significant Accounting Policies Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Aggregate amounts of cash and cash equivalents and the restricted cash Security Deposit Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Research and Development Expense [Member] Research and development General and Administrative Expense [Member] General and administrative Performance Shares [Member] Performance stock units Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-Based Compensation Expense Share-Based Payment Arrangement, Expense Stock-based compensation expense Total stock-based compensation expense Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to the related party Janssen Biotech Inc. Janssen Represents the Takeda Pharmaceuticals USA Inc., with which the company has entered into a worldwide license and collaboration agreement. Takeda Pharmaceuticals [Member] Takeda Pharmaceuticals Represents information relating to amended and restated agreement. Restated Agreement Represents information relating to license and collaboration agreement. License and Collaboration Agreement [Member] License and collaboration agreement Product and Service [Axis] Product and Service [Domain] License and Service [Member] License And Service License and Maintenance [Member] License and Maintenance Represents the information pertaining to development services. Development Services [Member] Development Services Represents the information pertaining to Rusfertide clinical trial supplies. Fusfertide Clinical Trial Supplies [Member] Rusfertide clinical trial supplies Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Represents the information pertaining to FDA approval of ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients over 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Food And Drug Administration Approval Of Icotyde [Member] FDA approval of ICOTYDE Represents the information pertaining to phase three clinical trial for rusfertide in PV Phase Three Clinical Trial For Rusfertide In PV [Member] Phase 3 clinical trial for rusfertide in PV Represents the information pertaining to FDA approval of an NDA for rusfertide in PV. Food And Drug Administration Approval Of New Drug Application For Rusfertide In PV [Member] Food And Drug Administration approval Of new drug application for rusfertide in PV Represents the information pertaining to acceptance of an NDA filing by the FDA for a second indication. Acceptance Of New Drug Application Filed By Food And Drug Administration Approval For Second Indication [Member] Acceptance of New Drug Application filed by Food And Drug Administration approval for second indication Represents the information pertaining to acceptance of an NDA filing by the FDA for a third indication. Acceptance Of New Drug Application Filed By Food And Drug Administration Approval For Third Indication [Member] Acceptance of an NDA filing by the FDA for a third indication Represents the information pertaining to FDA approval of an NDA for a second indication. Food And Drug Administration Approval Of New Drug Application For Second Indication [Member] Food And Drug Administration approval of New Drug Application for second indication Represents the information pertaining to FDA approval of an NDA for a third indication. Food And Drug Administration Approval Of New Drug Application For Third Indication [Member] FDA approval of an NDA for a third indication Represents information pertaining to first regulatory approval in three European countries for approval of rusfertide in PV. First Regulatory Approval In Three European Countries [Member] First regulatory approval in three European countries Represents information pertaining to first regulatory approval for rusfertide in PV in Japan. First Regulatory Approval In Japan [Member] First regulatory approval in japan Scenario [Axis] Scenario [Domain] Exercise of full opt-out right. Exercise of Full Opt-out Right [Member] Exercise of full opt-out right Exercise of full opt out right during the initial opt out period. Exercise of Full Opt-out Right During The Initial Opt-out Period (Member) Exercise of full opt out right during the initial opt out period The amount of cash inflow from milestone payments under the license and collaboration agreement. Proceeds from Milestone Payments Represents upcoming potential development and regulatory milestone payments receivable. Upcoming Potential Development and Regulatory Milestones Payments Upcoming potential development and regulatory milestone payments receivable The percentages on net product sales. Percentages Royalties on Net Product Sales Percentage of royalties on net product sales Represents the amount received from a collaborative arrangement. Collaborative Arrangement, Eligible Amount Received Non-refundable upfront payment Represents the percentage of royalties on net sales. Percentage of Royalties on Net Sales Percent Percentage of royalties on ex-U.S. net sales Percentage of royalties Represents the milestone payment amount eligible to receive from a collaborative arrangement. Collaborative Arrangement, Milestone Payment, Eligible to Receive Collaborative arrangement, milestone payment, eligible to receive Represents the profit sharing ration between the company and the counterparty under the agreement. Collaborative Agreement Profit Share, Percentage Profit (loss) share on U.S. profits and losses Represents the milestone additional payment eligible to receive from a collaborative arrangement. Collaborative Arrangement Milestone Additional Payment Eligible To Receive Additional payment eligible to receive from a collaborative arrangement Revenue, Remaining Performance Obligation, Amount Final transaction price The amount of upfront payment based on the agreement. Collaborative Agreement Upfront Payment Upfront payment Contract with Customer, Liability, Revenue Recognized Revenue recognized Amount of cost reimbursement. Cost Reimbursement Cost reimbursement Contract with Customer, Liability Contract with customer, deferred revenue contract liability Contract with Customer, Asset, after Allowance for Credit Loss, Current Contract asset Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Recognized revenue from deferred revenue contract liability Fair Value, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value, Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Investment Type [Axis] Investments [Domain] Money Market Funds [Member] Money market funds Certificates of Deposit [Member] Certificates of deposit This category includes information about debt securities issued by the United States Department of the Treasury and Agency. U.S. Treasury and agency securities U.S. Treasury and agency securities Commercial Paper [Member] Commercial paper Corporate Debt Securities [Member] Corporate debt securities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Assets, Fair Value Disclosure Total financial assets Schedule cash equivalents and available for sale securities. Schedule Cash Equivalents and Available for Sale Securities [Table] Schedule Cash Equivalents and Available-for-Sale Securities [Table] Cash and Cash Equivalents [Axis] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Cash Equivalents and Available for Sale Securities [Line Items] Cash Equivalents and Marketable Securities This item represents the cost of debt and equity securities, including cash equivalents which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. Cash Equivalents And Marketable Securities Amortized Cost Total cash equivalents and marketable securities, Amortized Cost Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as cash equivalents and marketable securities. Cash Equivalents And Marketable Securities Gross Unrealized Gain Total cash equivalents and marketable securities, Gross Unrealized Gains Amount of unrealized loss before deducting unrealized gain on investments in cash equivalents and marketable securities. Cash Equivalents And Marketable Securities Gross Unrealized Loss Total cash equivalents and marketable securities, Gross Unrealized Losses The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading. Cash Equivalents And Marketable Securities Fair Value Total cash equivalents and marketable securities, Fair Value Total cash equivalents and marketable securities Investments and Cash [Abstract] Classified as: Cash Equivalents, at Carrying Value Cash equivalents Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract] Contractual maturities Represents the maximum period of current contractual maturities. Current Contractual Maturities, Maximum Period Maximum period of current contractual maturities Represents the minimum period of noncurrent contractual maturities. Noncurrent Contractual Maturities, Minimum Period Minimum period of noncurrent contractual maturities Represents the maximum period of contractual maturities. Noncurrent Contractual Maturities, Maximum Period Maximum period of Noncurrent contractual maturities Marketable Security, Realized Gain (Loss) Realized Gain (loss) Represents credit-related losses to be recognized. Credit-related Losses To Be Recognized Credit-related losses to be recognized Prepaid Expense and Other Assets, Current [Abstract] Prepaid Expenses and Other Current Assets Interest Receivable, Current Accrued interest receivable Amount of asset related to consideration paid in advance for Prepaid manufacturing of clinical materials that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Manufacturing of Clinical Materials Prepaid clinical and research related expenses Prepaid Insurance Prepaid insurance Amount of asset related to consideration paid in advance for licenses that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Licenses Prepaid licenses Other Prepaid Expense, Current Other Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] This member stands for laboratory equipment. Laboratory Equipment Laboratory equipment This member stands for furniture and computer equipment. Furniture and Computer Equipment Furniture and computer equipment Leasehold Improvements [Member] Leasehold improvements Property, Plant and Equipment [Line Items] Property and Equipment Property, Plant and Equipment, Gross Total property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation Accrued Expenses and Other Payables Current portion of accrued clinical and research related expenses. Accrued Clinical and Research Related Expenses Current Accrued clinical and research related expenses Accrued Employee Benefits, Current Accrued employee related expenses Accrued Professional Fees, Current Accrued professional service fees Other Accrued Liabilities, Current Other Accrued Liabilities, Current Total accrued expenses and other payables Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] This member represents transactions associated with the Securities Purchase Agreement with certain accredited investors (each, an "Investor" and, collectively, the "Investors"). Investors Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private Placement Subsidiary, Sale of Stock [Line Items] Stockholders' Equity Class of Warrant or Right, Date from which Warrants or Rights Exercisable Warrants exercisable date Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price (per share) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued to purchase common stock, number of shares The minimum percentage of common stock held by investors for not exercise of warrants. Minimum Percentage of Common Stock Held by Investors for Not Exercise of Warrants Minimum percentage of common stock held by investors for not exercise of warrants Net Income (Loss) Attributable to Parent [Abstract] Numerator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator: Weighted Average Number of Shares Outstanding, Diluted, Adjustment Dilutive effect of common stock equivalents Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities (in shares) Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Segment Reporting Number of Operating Segments Number of operating segments It represents number of reportable segment not disclosed. Number Of Reportable Segments Not Disclosed [Flag] Number of reportable segment not disclosed Consolidation Items [Axis] Consolidation Items [Domain] Operating Segments [Member] Operating segment Segments [Axis] Segments [Domain] Represents the member information pertaining to single reportable segment. Single Reportable Segment [Member] Single reportable segment The aggregate cost of discovery department expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) incurred during the reporting period. Cost Of Revenue, Discovery Expenses, Excluding Employee Expense (benefit) And Allocation Share Based Compensation Expenses Discovery department expense (excluding employee wages and benefits, stock-based compensation and expense allocations) The aggregate cost of development department expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) incurred during the reporting period. Cost Of Revenue, Development Expenses, Excluding Employee Expense (benefit) And Allocation Share Based Compensation Expenses Development department expense (excluding employee wages and benefits, stock-based compensation and expense allocations) The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line excluding employee expense (benefit) and share based compensation. General and Administrative Expense, Excluding Employee Expense (benefit) And Allocation Share Based Compensation Expenses General and administrative expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) The amount of employee expense (benefit) related to discovery. Employee Expense (Benefit) Related to Discovery Employee wages and benefits - discovery The amount of employee expense (benefit) related to development. Employee Expense (Benefit) Related to Development Employee wages and benefits - development The amount of employee expense (benefit)related to general and administrative affairs. Employee Expense (Benefit) Related to General and Administrative Affairs Employee wages and benefits - general and administrative Segment Reporting, Other Segment Item, Amount Other segment items Segment Reporting, Other Segment Item, Composition, Description Segment reporting other item Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Events Represents the information pertaining to the scenario, in which annual net sales in up to $1.5 billion. Annual Net Sales Upto 1.5 Billion [Member] Annual net Sales Up to 1.5 billion Represents the information pertaining to the scenario, in which annual net sales in above $1.5 billion. Annual Net Sales Above 1.5 Billion [Member] Annual net sales above 1.5 billion Weighted Average [Member] Weighted average Subsequent Event [Line Items] Subsequent Events Amount of maximum sales milestone revenue. Maximum Sales Milestone Revenue Milestone revenue Amount of annual net sales determining the royalty percentage under the collaborative agreement. Collaborative Arrangement, Threshold Annual Net Sales Annual net sales Represents information related to Dinesh V. Patel. Dinesh V. Patel [Member] Dinesh V. Patel Represents information related to William Waddill. William Waddill [Member] William Waddill